Prostate Cancer

Coloplast has the ambition to use this new platform to grow in the expanding urology device market.

Upon closing of the deal, the combined annualised gross sales of Coloplast's urology and continence care products is estimated at around DKK 3 billion (USD 0.5 billion) corresponding to approximately 37% of group sales.The contemplated acquisition also gives Coloplast an important expansion of its business in the US market, taking annualised sales of Coloplast's urology and continence care products in this market to around DKK 700M (USD 115M) and substantially increasing its US sales force.Coloplast's CEO, Sten Scheibye, says:"This acquisition would significantly increase the scope of our continence care division in line with our strategy; it would allow us to provide a broad range of products to our customers.

In addition it would give us a stronger base in the US and would bring long-term value creation and benefits to all our stakeholders.

The transaction would clearly be a very important step towards realisi...

Read more...